[What does remain about bronchopulmonary dysplasia?]

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Respiratory Physiology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants, stemming from initial respiratory issues and pulmonary immaturity.
• Historically, BPD posed a significant mortality risk (up to 20%) for infants requiring prolonged mechanical ventilation in neonatal intensive care units.
• Despite a rising preterm birth rate, substantial progress has been made in managing BPD.

Discussion:

• Current preventive strategies include antenatal corticosteroids, exogenous surfactant administration, and improved ventilatory support techniques.
• Enhanced neonatal care, pain management, and nutritional support play crucial roles in BPD management.
• While inhaled corticosteroids have not proven effective, salbutamol spray aids in reducing bronchospasm and improving respiratory compliance.

Key Insights:

• Significant advancements in neonatal care and preventive therapies are leading to a regression in the incidence and severity of bronchopulmonary dysplasia.
• The long-term functional impairment associated with BPD into adulthood is a critical concern, with current data suggesting a more optimistic outlook for current generations.
• Despite challenges, the overall trend indicates a decrease in BPD, though predicting the future remains complex due to the high number of premature births.

Outlook:

• Further reduction in BPD incidence may be achieved through enhanced collaboration between obstetricians and pediatricians.
• Expanding the use of antenatal corticosteroid therapy and refining continuous positive airway pressure (CPAP) ventilation are key areas for future prevention.
• Continued research and development in neonatal respiratory support and therapeutic interventions are essential for improving outcomes for premature infants at risk of BPD.